- Home
- VNRX vs ACCS Comparison
VNRX vs ACCS Comparison
Compare VNRX & ACCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VNRX | ACCS |
|---|---|---|
| Founded | N/A | 1988 |
| Country | United States | United States |
| Employees | N/A | 113 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Publishing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.2M | 35.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | VNRX | ACCS |
|---|---|---|
| Price | $0.28 | $9.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $3.17 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 2.6M | 16.3K |
| Earning Date | 11-13-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,472,007.00 | ★ $22,646,000.00 |
| Revenue This Year | $55.33 | $0.18 |
| Revenue Next Year | $493.79 | $7.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 14.48 | ★ 42.30 |
| 52 Week Low | $0.27 | $7.72 |
| 52 Week High | $0.94 | $13.35 |
Technical Indicators
Market Signals| Indicator | VNRX | ACCS |
|---|---|---|
| Relative Strength Index (RSI) | 32.86 | 53.37 |
| Support Level | $0.28 | $7.75 |
| Resistance Level | $0.34 | $9.26 |
| Average True Range (ATR) | 0.03 | 0.41 |
| MACD | 0.00 | 0.17 |
| Stochastic Oscillator | 11.30 | 81.82 |
Price Performance
Historical ComparisonAbout VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
About ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.